TY - JOUR T1 - Longitudinal change in ultrasound measurement of rectus femoris cross-sectional area in COPD JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2016.PA1566 VL - 48 IS - suppl 60 SP - PA1566 AU - Alex Labey AU - J.L. Canavan AU - C.M. Nolan AU - S.E. Jones AU - S.S.C. Kon AU - M.I. Polkey AU - M. Maddocks AU - W.D.C. Man Y1 - 2016/09/01 UR - http://erj.ersjournals.com/content/48/suppl_60/PA1566.abstract N2 - Background: Ultrasound measurement of rectus femoris cross sectional area (RFCSA) is a validated, reproducible surrogate marker of quadriceps muscle mass in COPD, and is correlated strongly with quadriceps strength. However longitudinal validity of RFCSA has not been determined.Method: RFCSA, quadriceps maximum voluntary contraction (QMVC), fat free mass index (FFMI) determined by bioelectrical impedance analysis, lower limb muscle physical performance (5 repetition sit to stand:5STS; 4 metre gait speed:4MGS) were measured in 42 patients with COPD at baseline (T0) and at 12 months follow-up (T1).Results: At T0, RFCSA was correlated strongly with QMVC and FFMI (r=0.76, 0.65; both p<0.001), moderately with BMI and QMVCpeak /Ht2 (r=0.52, 0.42; both p<0.01), and weakly with 4MGS (r=0.32; p=0.04). Table 1 shows changes in outcome measures over 1 year. There was no significant correlation between change in RFCSA and change in QMVC, FFMI, BMI, 5STS or 4MGS (r=0.15, 0.11, 0.30, -0.02, 0.20; all p>0.20). View this table:TABLE 1 Change in outcome measuresConclusion: Change in RFCSA is not a surrogate marker of change in lower limb muscle strength or performance in COPD. ER -